Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.
Future researches targeted at elucidating interfacial-bulk protein interactions, unraveling interfacial behavior through in silico tools, exploring connection between interfacial-industrial processing ...
European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.
People with diabetes should eat as much protein as people who don't have diabetes. In a healthy diet, roughly 10% to 35% of your daily calories should come from protein. Protein itself does not have ...
Before choosing the best protein powders, our testers and dietitians evaluated more than 100 different animal-based and whey protein powders, considering factors like ingredients, taste ...
Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...
Credit: Bloomberg via Getty Images. Sage Therapeutics has rejected Biogen’s $469m takeover offer, with its board of directors unanimously concluding that the bid “significantly undervalues” the ...
Whether to block or stimulate GIP has become a hot debate in obesity research. Some scientists hypothesize that stimulating GIP, as Zepbound does, could desensitize the protein on pancreatic cells ...
Sage Therapeutics knows it needs to do something. But it doesn’t want to sell to its partner Biogen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback